Introducing LADR4 - A Platform Technology Solution to Make Drug Repurposing a Viable Solution

There are over 9,000 Rare Diseases with over 400M+ people affected and 90% diseases with no approved therapies. Repurposing can be a solution as it can cut the time to new therapies to <5 years and cost to more than 1/20 ^th of current projected costs of developing an NCE. Yet there is no significant effort on repurposing, the primary reason is that there is no security to investors due to lack of intellectual property protection.

LADR ⁴ (Ligand Assisted Drug Repurposing Repositioning Rescuing and Reprofiling) provides this missing security to investors and hence can make repurposing a viable and sustainable effort to help address this significant gap of therapeutics for rare diseases. It allows for generic drugs to be re-patented under Composition of Matter claims and at the same time not requiring a full pre-clinical and clinical development by regulators. The most advanced drug using this platform is currently in Phase III trials in the US and Phase I trials in the UK.

Additionally, four other US companies have licensed drugs based on this platform, two have gone public on the NASDAQ and PTOs in US, EU, China and Japan have issued Composition of Matter claims on drugs using this platform

Finally, a solution to make repurposing viable and investable for patients and investors alike.